SCHEMBL29943508

SCHEMBL29943508

CCOC(=O)Cc1c(F)cccc1Cl

nearest known ligand 0.60

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 8/20 0.60
MEN1 O00255 4/20 0.60
ATM Q13315 1/20 0.60
SMN1; SMN2 Q16637 4/20 0.58
LMNA P02545 1/20 0.58
ALDH1A1 P00352 3/20 0.56
ALOX15 P16050 1/20 0.56
TDP1 Q9NUW8 1/20 0.56
RXFP1 Q9HBX9 1/20 0.56
POLB P06746 2/20 0.54
KDM4E B2RXH2 1/20 0.54
TSHR P16473 1/20 0.54
MAPT P10636 2/20 0.54
HTT P42858 1/20 0.54
GAA P10253 1/20 0.54
NPC1 O15118 2/20 0.53
RAB9A P51151 2/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5252336 1.00 KMT2A (0.60) KMT2AMEN1ATMSMN1; SMN2LMNA
SCHEMBL1429298 0.89 AKR1B1 (0.55) KMT2AMEN1ATMSMN1; SMN2LMNA
SCHEMBL1867904 0.89 NLRP3 (0.54) KMT2AMEN1ATMSMN1; SMN2LMNA
SCHEMBL4331423 0.88 SMN1; SMN2 (0.56) KMT2AMEN1ATMSMN1; SMN2LMNA
Ammonia Solution, Strong SCHEMBL27532390 0.87 AKR1B1 (0.53) KMT2AMEN1ATMSMN1; SMN2LMNA
SCHEMBL7638197 0.85 KMT2A (0.56) KMT2AMEN1ATMSMN1; SMN2LMNA
SCHEMBL12023029 0.84 NLRP3 (0.50) KMT2AMEN1ATMSMN1; SMN2LMNA
SCHEMBL838467 0.84 SMN1; SMN2 (0.74) KMT2AMEN1SMN1; SMN2LMNAALDH1A1
SCHEMBL31514215 0.84 NLRP3 (0.54) KMT2AMEN1ATMLMNAALDH1A1
SCHEMBL23425650 0.83 CA12 (0.50) KMT2AMEN1ATMSMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4051671-A1 FLUORINATED QUINOLINE, QUINOXALINE AND BENZO[B][1,4]OXAZINE DERIVATIVES AS DIHYDROOROTATE DEHYDROGENASE (DHODH) INHIBITORS FOR THE TREATMENT OF CANCER, AUTOIMMUNE AND INFLAMMATORY DISEASES Janssen Biotech, Inc. (US) 2022-09-07 EP disclosed